Find Icotrokinra manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2763602-16-8, Icotrokinra [inn], Muw8fp7hnz, Schembl23656544, Ex-a9714, Hy-p10587
Molecular Formula
C90H120N20O22S2
Molecular Weight
1898.2  g/mol
InChI Key
IVFNYXYPMJQSGF-QMRCQSNESA-N
FDA UNII
MUW8FP7HNZ

Icotrokinra
1 2D Structure

Icotrokinra

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4S)-4-[[4-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-19-acetamido-7-(4-acetamidobutyl)-16-(2-amino-2-oxoethyl)-13-[(1R)-1-hydroxyethyl]-3,3,20,20-tetramethyl-10-[(7-methyl-1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-[4-(2-aminoethoxy)phenyl]propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]oxane-4-carbonyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[(2-amino-2-oxoethyl)-methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid
2.1.2 InChI
InChI=1S/C90H120N20O22S2/c1-48-16-14-20-59-57(46-97-72(48)59)42-64-79(122)99-60(21-12-13-34-96-50(3)112)77(120)108-75(89(7,8)134-133-88(5,6)74(98-51(4)113)84(127)104-66(44-69(93)115)81(124)107-73(49(2)111)83(126)102-64)85(128)103-62(39-52-23-26-58(27-24-52)132-37-32-91)78(121)100-63(40-53-22-25-55-18-10-11-19-56(55)38-53)82(125)109-90(30-35-131-36-31-90)87(130)106-61(28-29-71(117)118)76(119)101-65(43-68(92)114)80(123)105-67(41-54-17-15-33-95-45-54)86(129)110(9)47-70(94)116/h10-11,14-20,22-27,33,38,45-46,49,60-67,73-75,97,111H,12-13,21,28-32,34-37,39-44,47,91H2,1-9H3,(H2,92,114)(H2,93,115)(H2,94,116)(H,96,112)(H,98,113)(H,99,122)(H,100,121)(H,101,119)(H,102,126)(H,103,128)(H,104,127)(H,105,123)(H,106,130)(H,107,124)(H,108,120)(H,109,125)(H,117,118)/t49-,60+,61+,62+,63+,64+,65+,66+,67+,73+,74-,75-/m1/s1
2.1.3 InChI Key
IVFNYXYPMJQSGF-QMRCQSNESA-N
2.2 Other Identifiers
2.2.1 UNII
MUW8FP7HNZ
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2763602-16-8

2. Icotrokinra [inn]

3. Muw8fp7hnz

4. Schembl23656544

5. Ex-a9714

6. Hy-p10587

7. Glycinamide, N-acetyl-3-mercapto-l-valyl-l-asparaginyl-l-threonyl-7-methyl-l-tryptophyl-n6-acetyl-l-lysyl-3-mercapto-l-valyl-o-(2-aminoethyl)-l-tyrosyl-3-(2-naphthalenyl)-l-alanyl-4-aminotetrahydro-2h-pyran-4-carbonyl-l-alpha-glutamyl-l-asparaginyl-3-(3-pyridinyl)-l-alanyl-n2-methyl-, Cyclic (1-->6)-disulfide

2.4 Create Date
2022-02-06
3 Chemical and Physical Properties
Molecular Weight 1898.2 g/mol
Molecular Formula C90H120N20O22S2
XLogP3-3.4
Hydrogen Bond Donor Count20
Hydrogen Bond Acceptor Count26
Rotatable Bond Count40
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area709
Heavy Atom Count134
Formal Charge0
Complexity4100
Isotope Atom Count0
Defined Atom Stereocenter Count12
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Fujian Genohope Biotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content

Icotrokinra

About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and solutions, offering global API and preparation production services. Co-founded by...

Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and solutions, offering global API and preparation production services. Co-founded by New Hope Hosencare Brothers and Taiwan Genovior Biotech Corporation, the company operates in the Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone in Fujian, China. With a 70,000-square-meter facility, 11 production lines, and GMP-compliant operations, Fujian Genohope meets regulatory requirements for China, the U.S., and international markets, ensuring high-quality peptide therapeutics worldwide.
Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 09, 2025

blank

01

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

May 09, 2025

blank

Details:

JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 10, 2025

blank

02

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

April 10, 2025

blank

03

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

March 17, 2025

blank

Details:

JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2025

blank

04

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

March 10, 2025

blank

Details:

JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 08, 2025

blank

05

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

March 08, 2025

blank

06

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

February 04, 2025

blank

Details:

JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Protagonist Therapeutics

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 18, 2024

blank

07

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

November 18, 2024

blank

Details:

JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 03, 2024

blank

08

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

September 03, 2024

blank

Details:

Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Protein

Sponsor: JANSSEN BIOTECH

Deal Size: $987.5 million Upfront Cash: $50.0 million

Deal Type: Licensing Agreement December 13, 2023

blank

09

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : $50.0 million

December 13, 2023

blank

Details:

JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.


Lead Product(s): Icotrokinra,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Protagonist Therapeutics

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 27, 2023

blank

10

Pharmaconex
Not Confirmed
Pharmaconex
Not Confirmed

Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

November 27, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 2763602-16-8 / Icotrokinra API manufacturers, exporters & distributors?

Icotrokinra manufacturers, exporters & distributors 1

82

PharmaCompass offers a list of Icotrokinra API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Icotrokinra manufacturer or Icotrokinra supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Icotrokinra manufacturer or Icotrokinra supplier.

PharmaCompass also assists you with knowing the Icotrokinra API Price utilized in the formulation of products. Icotrokinra API Price is not always fixed or binding as the Icotrokinra Price is obtained through a variety of data sources. The Icotrokinra Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Icotrokinra

Synonyms

2763602-16-8, Icotrokinra [inn], Muw8fp7hnz, Schembl23656544, Ex-a9714, Hy-p10587

Cas Number

2763602-16-8

Unique Ingredient Identifier (UNII)

MUW8FP7HNZ

Icotrokinra Manufacturers

A Icotrokinra manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Icotrokinra, including repackagers and relabelers. The FDA regulates Icotrokinra manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Icotrokinra API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Icotrokinra manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Icotrokinra Suppliers

A Icotrokinra supplier is an individual or a company that provides Icotrokinra active pharmaceutical ingredient (API) or Icotrokinra finished formulations upon request. The Icotrokinra suppliers may include Icotrokinra API manufacturers, exporters, distributors and traders.

click here to find a list of Icotrokinra suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Icotrokinra GMP

Icotrokinra Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Icotrokinra GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Icotrokinra GMP manufacturer or Icotrokinra GMP API supplier for your needs.

Icotrokinra CoA

A Icotrokinra CoA (Certificate of Analysis) is a formal document that attests to Icotrokinra's compliance with Icotrokinra specifications and serves as a tool for batch-level quality control.

Icotrokinra CoA mostly includes findings from lab analyses of a specific batch. For each Icotrokinra CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Icotrokinra may be tested according to a variety of international standards, such as European Pharmacopoeia (Icotrokinra EP), Icotrokinra JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Icotrokinra USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty